VIB is a life-sciences research institute performing basic research with a strong focus on translating scientific results into pharmaceutical, agricultural and industrial applications. Over the past few years, NautaDutilh has assisted VIB with the incorporation of several spin-offs.
The most recent project we worked on with VIB was the incorporation of Aelin Therapeutics, a privately held Belgian biotherapeutics company which has secured a EUR 27 million investment to pioneer a novel development to create a completely new class of antibiotics and first-in-class therapeutics for use against high-value undruggable human targets.
The technology, known as Pept-ins™, harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein.
NautaDutilh's team, led by Elke Janssens and Florence Verhoestraete, assisted VIB.
View VIB's official press release here.